99% Purity Erlotinib Hcl Erlotinib Hydrochloride Pharmaceutical Active Ingredients CAS 183319-69-9 White To Off White Powder
Erlotinib hydrochloride CAS: 183319-69-9
Product Name: Erlotinib hydrochloride
Cas No.: 183319-69-9
Molecular Weight: 429.9
Single impurity ≤0.1%
Melting Point :219-221 °C(Experimental)(Solv: methanol )
4-Quinazolinamine, N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-, monohydrochloride (9CI)
Statement:The APls provided by our company are only for scientific research and drug registration,not for any commercial purpose!
The Cas number of Erlotinib hydrochloride is 183319-69-9 with the molecular formula of C22H24ClN3O4 and the molecular weight of 429.9.Normally We have some inventory, if there is more demand, our longest delivery time is not more than 4 weeks . We have been in the conventional production of this product . Our process is mature and stable. Welcome to contact us if you have any questions
Erlotinib hydrochloride is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer. Similar to gefitinib, erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. Erlotinib has recently been shown to be a potent inhibitor of JAK2V617F activity. JAK2V617F is a mutant of tyrosine kinase JAK2, is found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. The study suggests that erlotinib may be used for treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
For the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
Erlotinib hydrochloride Description
Erlotinib hydrochloride (trade name Tarceva) is a drug used to treat non-small cell lung cancer (NSCLC), pancreatic cancer and several other types of cancer. It is a receptor tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).
Erlotinib hydrochloride Application
1. Erlotinib hydrochloride is a kind of small molecule epidermal growth factor receptor tyrosine kinase reversible inhibitor. It is mainly used for the second-line or third-line treatment of locally advanced or metastatic non-small cell lung cancer and for the treatment of pancreatic cancer.
1)Non-small cell lung cancer (NSCLC).It is used as first-line treatment for metastatic NSCLC in patients with tumors that have certain epidermal growth factor receptor (EGFR) mutations.It is used for locally advanced or metastatic NSCLC in patients who have already been treated with chemotherapy.
2)Pancreatic cancer. It is used with gemcitabine hydrochloride in patients whose disease cannot be removed by surgery or has metastasized.Erlotinib hydrochloride is also being studied in the treatment of other types of cancer.
2. HER-1/EGFR tyrosine kinase inhibitors.
3. Erlotinib has shown a survival benefit in the treatment of lung cancer in phase III trials. The SATURN (Sequential Tarceva in Unresectable NSCLC) study found that erlotinib added to chemotherapy improved overall survival by 19%, and improved progression-free survival (PFS) by 29%, when compared to chemotherapy alone.
Steroid Hormone Powder:
Testosterone Sustanon 250
Other topical pain relief powders: